Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease.
| Author | |
|---|---|
| Abstract | :
Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis. |
| Year of Publication | :
0
|
| Journal | :
PloS one
|
| Volume | :
13
|
| Issue | :
1
|
| Number of Pages | :
e0190999
|
| Date Published | :
2018
|
| URL | :
http://dx.plos.org/10.1371/journal.pone.0190999
|
| DOI | :
10.1371/journal.pone.0190999
|
| Short Title | :
PLoS One
|
| Download citation |